Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Interest Expenses (2016 - 2025)

Zevra Therapeutics' Interest Expenses history spans 11 years, with the latest figure at $1.9 million for Q4 2025.

  • For Q4 2025, Interest Expenses fell 11.21% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $8.0 million, up 8.52%, while the annual FY2025 figure was $8.0 million, 8.52% up from the prior year.
  • Interest Expenses reached $1.9 million in Q4 2025 per ZVRA's latest filing, down from $2.1 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $2.3 million in Q3 2024 to a low of $5000.0 in Q4 2021.
  • Average Interest Expenses over 5 years is $966388.9, with a median of $550500.0 recorded in 2023.
  • Peak YoY movement for Interest Expenses: plummeted 99.57% in 2021, then surged 6600.0% in 2022.
  • A 5-year view of Interest Expenses shows it stood at $5000.0 in 2021, then soared by 6600.0% to $335000.0 in 2022, then skyrocketed by 125.67% to $756000.0 in 2023, then surged by 190.21% to $2.2 million in 2024, then decreased by 11.21% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Interest Expenses are $1.9 million (Q4 2025), $2.1 million (Q3 2025), and $2.0 million (Q2 2025).